Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16226
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPassey, Samantha L-
dc.contributor.authorHansen, Michelle J-
dc.contributor.authorBozinovski, Steven-
dc.contributor.authorMcDonald, Christine F-
dc.contributor.authorHolland, Anne E-
dc.contributor.authorVlahos, Ross-
dc.date2016-06-29-
dc.date.accessioned2016-09-12T05:32:36Z-
dc.date.available2016-09-12T05:32:36Z-
dc.date.issued2016-10-
dc.identifier.citationPharmacology & Therapeutics 2016; 166: 56-70en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16226-
dc.description.abstractChronic obstructive pulmonary disease (COPD) is a progressive lung disease that constitutes a major global health burden. A significant proportion of patients experience skeletal muscle wasting and loss of strength as a comorbidity of their COPD, a condition that severely impacts on their quality of life and survival. At present, the lung pathology is considered to be largely irreversible; however, the inherent adaptability of muscle tissue offers therapeutic opportunities to tackle muscle wasting and potentially reverse or delay the progression of this aspect of the disease, to improve patients' quality of life. Muscle wasting in COPD is complex, with contributions from a number of factors including inflammatory cytokines, oxidative stress, growth and anabolic hormones, nutritional status, and physical activity. In this review, we discuss current and emerging therapeutic approaches to treat muscle wasting in COPD, including a number of pharmacological therapies that are in development for muscle atrophy in other pathological states that could be of relevance for treating muscle wasting in COPD patients.en_US
dc.subjectChronic obstructive pulmonary disease (COPD)en_US
dc.subjectComorbiditiesen_US
dc.subjectPulmonary rehabilitationen_US
dc.subjectSkeletal muscleen_US
dc.subjectTherapeutic strategiesen_US
dc.subjectWastingen_US
dc.titleEmerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary diseaseen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitlePharmacology & Therapeuticsen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationLung Health Research Centre, Department of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, the University of Melbourne, Institute for Breathing and Sleep, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Physiotherapy, La Trobe University and Alfred Health, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27373503en_US
dc.identifier.doi10.1016/j.pharmthera.2016.06.013en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherHolland, Anne E
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.openairetypeJournal Article-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptPhysiotherapy-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
1-s2.0-S0163725816301036-main.pdf907.59 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

12
checked on Mar 27, 2024

Download(s)

90
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.